Luteolin reversed anxiety and depressive-like behavior via modulation of the NF-κB/NLRP3 inflammasome axis in the hippocampus of rats subjected to sleep deprivation

Document Type : Original Article

Authors

1 Department of Sleep Disorders and Neuroses, Brain Hospital of Hunan Province (The Second People’s Hospital of Hunan Province), No. 427, Section 3, Furong Middle Road, Changsha, 410000, China

2 Department of Critical Medicine, Brain Hospital of Hunan Province (The Second People’s Hospital of Hunan Province), No. 427, Section 3, Furong Middle Road, Changsha, 410000, China

10.22038/ijbms.2024.75068.16277

Abstract

Objective(s): In this study, we assessed the impact of luteolin (LUT) on mood disorders (specifically anxiety and depression) induced by sleep deprivation (SD) by regulating pathways associated with neuroinflammation.
Materials and Methods: Rapid eye movement (REM) SD was employed to induce anxiety and depression in the animal subjects. The animals were treated with PAX (15 mg/kg, positive control) and LUT (10 and 20 mg/kg) for a duration of 21 days. The anxiety and depressive disorders were evaluated using behavioral tests. Following the sacrifice of the animals, hippocampal tissues were stored for molecular investigations.
Results: SD resulted in anxiety, as evidenced by the elevated plus maze test and open field test. Furthermore, the findings from the sucrose performance test, forced swimming test, and tail suspension test confirmed the presence of depressive-like behaviors in the animals. The nuclear factor kappa B (NF-κB) and NLR family pyrin domain containing 3 (NLRP3) inflammasome components, including apoptosis-associated speck-like protein containing a C-terminal caspase recruitment domain (ASC), NLRP3, and active Caspase-1, were up-regulated in the hippocampus (HC) of the animals subjected to REM SD. However, treatment with LUT demonstrated a significant reversal of the behavioral changes by modulating the NF-κB and NLRP3 inflammasome components in the HC.
Conclusion: It can be concluded that LUT demonstrated antidepressant effects via regulation of the NF-κB/NLRP3 inflammasome axis components in the HC. 

Keywords

Main Subjects

References

1. Rajaratnam SM, Arendt J. Health in a 24-h society. Lancet 2001;358:999-1005.
2. Roberts RE, Duong HT. The prospective association between sleep deprivation and depression among adolescents. Sleep 2014;37:239-244.
3. Chapman DP, Presley-Cantrell LR, Liu Y, Perry GS, Wheaton AG, Croft JB. Frequent insufficient sleep and anxiety and depressive disorders among US community dwellers in 20 states, 2010. Psychiatr Serv 2013;64:385-387.
4. Pace-Schott EF, Hobson JA. The neurobiology of sleep: Genetics, cellular physiology and subcortical networks. Nat Rev Neurosci 2002;3:591-605.
5. Franzen PL, Buysse DJ. Sleep disturbances and depression: Risk relationships for subsequent depression and therapeutic implications. Dialogues Clin Neurosci 2008;10:473-481.
6. Fang H, Tu S, Sheng J, Shao A. Depression in sleep disturbance: A review on a bidirectional relationship, mechanisms and treatment. J Cell Mol Med 2019;23:2324-2332.
7. Meerlo P, Havekes R, Steiger AJ. Chronically restricted or disrupted sleep as a causal factor in the development of depression. Curr Top Behav Neurosci 2015; 25: 459-81.
8. Buysse DJ, Angst J, Gamma A, Ajdacic V, Eich D, Rössler W. Prevalence, course, and comorbidity of insomnia and depression in young adults. Sleep 2008;31:473-480.
9. Havekes R, Vecsey CG, Abel T. The impact of sleep deprivation on neuronal and glial signaling pathways important for memory and synaptic plasticity. Cell Signal 2012; 24:1251-1260.
10. Zhang J-c, Yao W, Hashimoto K. Brain-derived neurotrophic factor (BDNF)-TrkB signaling in inflammation-related depression and potential therapeutic targets. Curr Neuropharmacol  2016;14:721-731.
11. Mueller AD, Meerlo P, McGinty D, Mistlberger RE. Sleep and adult neurogenesis: Implications for cognition and mood. Curr Top Behav Neurosci 2015; 25: 151-81.
12. Mokhtari T, Tu Y, Hu L. Involvement of the hippocampus in chronic pain and depression. Brain Sci Adv 2019; 5: 288-298.
13. Belleau EL, Treadway MT, Pizzagalli DA. The impact of stress and major depressive disorder on hippocampal and medial prefrontal cortex morphology. Biol Psychiatry 2019; 85: 443-453.
14. Farooq RK, Asghar K, Kanwal S, Zulqernain A. Role of inflammatory cytokines in depression: Focus on interleukin-1β. Biomed Rep 2017; 6:15-20.
15. Mokhtari T, Yue L-P, Hu L. Exogenous melatonin alleviates neuropathic pain-induced affective disorders by suppressing NF-κB/NLRP3 pathway and apoptosis. Sci Rep 2023;13:2111-2125.
16. DiSabato DJ, Quan N, Godbout JP. Neuroinflammation: The devil is in the details. J Neurochem 2016; 139: 136-153.
17. Mokhtari T, Uludag K. Role of NLRP3 Inflammasome in post-spinal-cord-injury anxiety and depression: molecular mechanisms and therapeutic implications. ACS Chem Neurosci 2023;15:56-70.
18. Zarebavani M, Baghaei Naeini F, Farahvash A, Moradi F, Dashti N. Resveratrol attenuates chronic social isolation stress‐induced affective disorders: Involvement of NF‐κB/NLRP3 axis.  J Biochem Mol Toxicol 2023;37:e23311.
19. Xia C-Y, Guo Y-X, Lian W-W, Yan Y, Ma B-Z, Cheng Y-C, et al. The NLRP3 inflammasome in depression: Potential mechanisms and therapies. Pharmacol Res 2023;187:106625-106641.
20. Moradi F, Dashti N, Farahvash A, Baghaei Naeini F, Zarebavani M. Curcumin ameliorates chronic Toxoplasma gondii infection-induced affective disorders through modulation of proinflammatory cytokines and oxidative stress. Iran J Basic Med Sci 2023;26:461-467.
21. Sagulenko V, Thygesen SJ, Sester DP, Idris A, Cridland JA, Vajjhala PR, et al. AIM2 and NLRP3 inflammasomes activate both apoptotic and pyroptotic death pathways via ASC. Cell Death Differ 2013;20:1149-1160.
22. Lin Y, Shi R, Wang X, Shen HM. Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr Cancer Drug Targets 2008;8:634-646.
23. Ashaari Z, Hadjzadeh M-A-R, Hassanzadeh G, Alizamir T, Yousefi B, Keshavarzi Z, et al. The flavone luteolin improves central nervous system disorders by different mechanisms: A review. J Mol Neurosci 2018; 65: 491-506.
24. Kou J-j, Shi J-z, He Y-y, Hao J-j, Zhang H-y, Luo D-m, et al. Luteolin alleviates cognitive impairment in Alzheimer’s disease mouse model via inhibiting endoplasmic reticulum stress-dependent neuroinflammation. Acta Pharmacol Sin 2022;43:840-849.
25. Coleta M, Campos MG, Cotrim MD, de Lima TCM, da Cunha AP. Assessment of luteolin (3′, 4′, 5, 7-tetrahydroxyflavone) neuropharmacological activity.  Behav Brain Res 2008; 189: 75-82.
26. Kao TK, Ou YC, Lin SY, Pan HC, Song PJ, Raung SL, et al. Luteolin inhibits cytokine expression in endotoxin/cytokine-stimulated microglia. J Nutr Biochem 2011;22:612-624. 
27. Mokhtari T, Lu M, El-Kenawy AE-M. Potential anxiolytic and antidepressant-like effects of luteolin in a chronic constriction injury rat model of neuropathic pain: Role of oxidative stress, neurotrophins, and inflammatory factors.  Int Immunopharmacol  2023;122:110520.
28. Nabavi SF, Braidy N, Gortzi O, Sobarzo-Sanchez E, Daglia M, Skalicka-Woźniak K, et al. Luteolin as an anti-inflammatory and neuroprotective agent: A brief review. Brain Res Bull 2015;119:1-11.
29. Mokhtari T. Targeting autophagy and neuroinflammation pathways with plant‐derived natural compounds as potential antidepressant agents. Phytother Res 2022;36:3470-3489.
30. Sur B, Lee BJ. Luteolin reduces fear, anxiety, and depression in rats with post-traumatic stress disorder. Anim Cells Syst 2022; 26:174-182.
31. Wang X, Wang Z, Cao J, Dong Y, Chen Y. Melatonin alleviates acute sleep deprivation-induced memory loss in mice by suppressing hippocampal ferroptosis. Front Pharmacol 2021;12:708645-708659.
32. Forbes NF, Stewart CA, Matthews K, Reid IC, behavior. Chronic mild stress and sucrose consumption: Validity as a model of depression. Physiology 1996;60:1481-1484.
33. Porsolt RD. Animal models of depression: Utility for transgenic research. Rev Neurosci 2000;11:53-58.
34. Talei S, Mokhtari T, Asadi I, Arab L, Hassanzadeh N, Hosseinjani E, et al. Flaxseed oil (Linum usitatissimum) attenuates restraint stress-induced depressive-like behavior: Upregulation of neurotrophic factors in CA1 region of hippocampus. J Contemp Med Sci 2021;7: 61-65.
35. Belviranlı M, Okudan N. The effects of Ginkgo biloba extract on cognitive functions in aged female rats: The role of oxidative stress and brain-derived neurotrophic factor. Behav Brain Res 2015;278:453-461.
36. Seyedhosseini Tamijani SM, Beirami E, Ahmadiani A, Dargahi L. Effect of three different regimens of repeated methamphetamine on rats’ cognitive performance. Cogn Process 2018;19:107-115.  
37. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2− ΔΔCT method. Methods 2001; 25: 402-408.
38. Mokhtari T, Akbari M, Malek F, Kashani IR, Rastegar T, Noorbakhsh F, et al. Improvement of memory and learning by intracerebroventricular microinjection of T3 in rat model of ischemic brain stroke mediated by upregulation of BDNF and GDNF in CA1 hippocampal region. Daru 2017; 25: 4-14.
39. Gonzalez-Castañeda RE, Galvez-Contreras AY, Martínez-Quezada CJ, Jauregui-Huerta F, Grcia-Estrada J, Ramos-Zuñiga R, et al. Sex-related effects of sleep deprivation on depressive- and anxiety-like behaviors in mice. Exp Anim 2016; 65: 97-107.
40. da Silva Rocha-Lopes J, Machado RB, Suchecki D. Chronic REM sleep restriction in juvenile male rats induces anxiety-like behavior and alters monoamine systems in the amygdala and hippocampus. Mol Neurobiol 2018; 55: 2884-2896.
41. Pokk P, Liljequist S, Zharkovsky A. Ro 15-4513 potentiates, instead of antagonizes, ethanol-induced sleep in mice exposed to small platform stress. Eur J Pharmacol 1996; 317: 15-20.
42. Pokk P, Väli M. Small platform stress increases exploratory activity of mice in staircase test. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25: 1435-1444.
43. Silva RH, Kameda SR, Carvalho RC, Takatsu-Coleman AL, Niigaki ST, Abílio VC, et al. Anxiogenic effect of sleep deprivation in the elevated plus-maze test in mice. Psychopharmacology 2004; 176: 115-122.
44. Pezzato FA, Paula HGMd, Bosqueiro JR, Hoshino K. Intake of sucrose solution and paradoxical sleep deprivation in the rat. Sleep Sci 2009; 2: 125-129.
45. Asakura W, Matsumoto K, Ohta H, Watanabe H. Effect of alpha 2-adrenergic drugs on REM sleep deprivation-induced increase in swimming activity. Pharmacol Biochem Behav 1993; 46: 111-115.
46. Lee AL, Ogle WO, Sapolsky RM. Stress and depression: Possible links to neuron death in the hippocampus. Bipolar Disord 2002; 4:117-128.
47. Parul, Mishra A, Singh S, Singh S, Tiwari V, Chaturvedi S, et al. Chronic unpredictable stress negatively regulates hippocampal neurogenesis and promote anxious depression-like behavior via upregulating apoptosis and inflammatory signals in adult rats. Brain Res Bull 2021;172:164-179.
48. Sapolsky RM. The possibility of neurotoxicity in the hippocampus in major depression: A primer on neuron death. Biol Psychiatry 2000;48:755-765.
49. Voorhees JL, Tarr AJ, Wohleb ES, Godbout JP, Mo X, Sheridan JF, et al. Prolonged restraint stress increases IL-6, reduces IL-10, and causes persistent depressive-like behavior that is reversed by recombinant IL-10. PLoS One 2013; 8: e58488-e58498.
50. Grippo AJ, Scotti M-AL. Stress and Neuroinflammation.  Inflammation in Psychiatry. 28: Karger Publishers; 2013. p. 20-32.
51. Zhou R, Wang F, Zhao G, Xia W, Peng D, Mao R, et al. Effects of tumor necrosis factor-α polymorphism on the brain structural changes of the patients with major depressive disorder. Transl Psychiatry 2018; 8: 1-9.
52. Goshen I, Kreisel T, Ben-Menachem-Zidon O, Licht T, Weidenfeld J, Ben-Hur T, et al. Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol Psychiatry 2008;13:717-728.
53. Zunszain PA, Anacker C, Cattaneo A, Choudhury S, Musaelyan K, Myint AM, et al. Interleukin-1β: A new regulator of the kynurenine pathway affecting human hippocampal neurogenesis. Neuropsychopharmacology 2012; 37: 939-949.
54. Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 inflammasome: An overview of mechanisms of activation and regulation. Int J Mol Sci 2019; 20: 3328-3351.
55. Stepanichev M, Dygalo NN, Grigoryan G, Shishkina GT, Gulyaeva N. Rodent models of depression: Neurotrophic and neuroinflammatory biomarkers. BioMed Res Int 2014: 2014: 932757-932776.
56. Wang M, Yan S, Zhou Y, Xie P. trans-Cinnamaldehyde Reverses Depressive-Like Behaviors in Chronic Unpredictable Mild Stress Rats by Inhibiting NF-κB/NLRP3 Inflammasome Pathway. Evid Based Complement Alternat Med 2020; 2020: 4572185-4572201.
57. Chávez-Castillo M, Núñez V, Nava M, Ortega Á, Rojas M, Bermúdez V, et al. Depression as a neuroendocrine disorder: Emerging neuropsychopharmacological approaches beyond monoamines. Adv Pharmacol Sci 2019; 2019: 7943481-7943500.
58. Liu T, Zhang L, Joo D, Sun S-C. NF-κB signaling in inflammation. Signal Transduct Target Ther 2017; 2: 17023.
59. Li DX, Wang CN, Wang Y, Ye CL, Jiang L, Zhu XY, et al. NLRP3 inflammasome-dependent pyroptosis and apoptosis in hippocampus neurons mediates depressive-like behavior in diabetic mice. Behav Brain Res 2020; 391:112684.
60. Sawmiller D, Li S, Shahaduzzaman M, Smith AJ, Obregon D, Giunta B, et al. Luteolin reduces Alzheimer’s disease pathologies induced by traumatic brain injury. Int J Mol Sci 2014;15:895-904.
61. Shen ML, Wang CH, Chen RY, Zhou N, Kao ST, Wu DC. Luteolin inhibits GABAA receptors in HEK cells and brain slices. Sci Rep 2016; 6: 27695-27705.
62. Zhu S, Lei S, Zhou S, Jin L, Zeng S, Jiang H, et al. Luteolin shows antidepressant-like effect by inhibiting and downregulating plasma membrane monoamine transporter (PMAT, Slc29a4). J Funct Foods 2019; 54: 440-448.
63. Ntalouka F, Tsirivakou A. Luteolin: A promising natural agent in management of pain in chronic conditions. Front Pain Res (Lausanne) 2023; 4: 1114428-1114446.
Iranian Journal of Basic Medical Sciences

Articles in Press, Accepted Manuscript
Available Online from 08 May 2024

Files

Share

How to cite

Statistics